Skip to main content
Clinical Trials/ACTRN12617000391370
ACTRN12617000391370
Recruiting
Phase 2

Role of Tranexamic acid on post operative blood loss and blood transfusion in intra capsular neck of femur fracture patients undergoing hip arthroplasty (total hip arthroplasty or hemiarthroplasty)

epean Hospital (Nepean Blue Mountain Local Health District)0 sites250 target enrollmentMarch 16, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
epean Hospital (Nepean Blue Mountain Local Health District)
Enrollment
250
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 16, 2017
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
epean Hospital (Nepean Blue Mountain Local Health District)

Eligibility Criteria

Inclusion Criteria

  • Patients with intra\-capsular neck of femur fractures undergoing hemiarthroplasty (cemented or uncemented) or total hip arthroplasty (cemented, hybrid or uncemented) within 48 hrs from the time of injury.

Exclusion Criteria

  • 1\.Neck of femur fractures requiring fixation by other methods e.g. by cannulated screws, dynamic hip screw or intra\-medullary nail device.
  • 2\.Patients presenting 48 hours from the time of injury. This includes patients transferred to Nepean hospital from other hospitals.
  • 3\.Contra\-indication to the administration of TA \-
  • Previous history of thrombosis
  • Active thromboembolic disease (DVT,PE and cerebral thrombosis)
  • Other contraindication to the use of TA :
  • Patients with acquired disturbances of colour vision
  • Patients with subarachnoid haemorrhage
  • Previous history of seizure
  • Creatinine clearance \< 30ml/min

Outcomes

Primary Outcomes

Not specified

Similar Trials